Pacific Biosciences is trading 5.9% up at $1.44, apparently on sector-driven biotech and technology strength.
- The Nasdaq Biotechnology Index rose 1.10% on September 22, 2026, while broader technology sentiment remained firm.
- No new company-specific announcement, earnings release, analyst action or filing clearly explains the move.
- Recent coverage centers on the previously reported 2026 outlook reduction and clinical-adoption challenges, not a new September 22 event.